NNOX240816P7500
- 0.72
- -0.01-1.37%
Nano X Imaging Newsroom
Trending Industry Today: SoundHound AI Leads Losses In NVIDIA Holdings Stocks
July 18th - The industry of $NVIDIA Holdings(LIST20882.US)$ is trending down in regular trading hours with 4 constituents down and SoundHound AI leading Losses.$SoundHound AI(SOUN.US)$ dips 5.91% to $
Trending Industry Today: Arm Holdings Leads Losses In NVIDIA Holdings Stocks
July 17th - The industry of $NVIDIA Holdings(LIST20882.US)$ is trending down in regular trading hours with 4 constituents down and Arm Holdings leading Losses.$Arm Holdings(ARM.US)$ slides 8.03% to $1
Trending Industry Today: SoundHound AI Leads Losses Pre-Market In NVIDIA Holdings Stocks
July 17th - The industry of $NVIDIA Holdings(LIST20882.US)$ is trending down in pre-market trading with 4 constituents down and SoundHound AI leading Losses.$SoundHound AI(SOUN.US)$ slides 4.45% to $5
Express News | NANO-X IMAGING Says Data For Nanox.AI To Be Presented At SCCT
Data Supporting Nanox.AI Cardiac Solution to Be Presented at 19th Annual Meeting of the Society of Cardiovascular Computed Tomography
PETACH TIKVA, Israel, June 25, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that data from
Trending Industry Today: Recursion Pharmaceuticals Leads Losses In NVIDIA Holdings Stocks
June 20th - The industry of $NVIDIA Holdings(LIST20882.US)$ is trending down in regular trading hours with 1 constituents up, 3 constituents down and Recursion Pharmaceuticals leading Losses.$Recursio
Are Business Services Stocks Lagging NanoX Imaging (NNOX) This Year?
Trending Industry Today: Recursion Pharmaceuticals Leads Gains In NVIDIA Holdings Stocks
June 12th - The industry of $NVIDIA Holdings(LIST20882.US)$ is trending up in regular trading hours with 4 constituents up and Recursion Pharmaceuticals leading Gains.$Recursion Pharmaceuticals(RXRX.U
Nvidia Owns These 4 Stocks. Here's How They're Doing.
Angela Palumbo Nvidia has been one of the best-performing stocks on Wall Street since 2023, amassing holdings in four companies along the way. So, how have these stocks been doing? First, a bit of c
Nano X Imaging | 6-K: Report of foreign private issuer (related to financial reporting)
Express News | Nano-X Imaging Entered Into Controlled Equity Offering Sales Agreement Relating To Issuance & Sale From Time To Time Of Ordinary Shares Of Up To $100M From Time To Time
Express News | Nano-X Imaging Ltd -May Offer & Sell Ordinary Shares Having an Aggregate Offering Price of up to $100 Mln From Time to Time
A. G. P. Initiates Nano X Imaging(NNOX.US) With Buy Rating, Announces Target Price $12
A. G. P. analyst Scott Henry initiates coverage on $Nano X Imaging(NNOX.US)$ with a buy rating, and sets the target price at $12.According to TipRanks data, the analyst has a success rate of 39.4% and
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks were rising late Wednesday afternoon with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 0.4%. The iShares Biotechnology ETF (IBB) climbed
Nanox Launches Artificial Intelligence Functionality in Second Opinions Platform
Nanox integrates FDA-cleared population health AI solutions into its Second Opinions serviceNew AI capabilities available to patients who submit chest and abdominal CT scans for second opinionsOfferin
Cantor Fitzgerald Reiterates Overweight on Nano X Imaging, Maintains $17 Price Target
Cantor Fitzgerald analyst Ross Osborn reiterates Nano X Imaging (NASDAQ:NNOX) with a Overweight and maintains $17 price target.
Nano-X Imaging Price Target Cut to $17.00/Share From $18.00 by Cantor Fitzgerald
Nano-X Imaging Price Target Cut to $17.00/Share From $18.00 by Cantor Fitzgerald
Nano-X Imaging Is Maintained at Overweight by Cantor Fitzgerald
Nano-X Imaging Is Maintained at Overweight by Cantor Fitzgerald
Express News | Cantor Fitzgerald Maintains Overweight on Nano X Imaging, Lowers Price Target to $17
Nanox Imaging (NASDAQ:NNOX) Making Progress, While Priced at a Premium